Several studies have demonstrated that treatment with enzyme-inducing antiepileptic drugs is associated with increased serum lipid levels. Eslicarbazepine acetate (ESL) is a novel antiepileptic drug specifically designed with the objective to identify carbamazepine and oxcarbazepine analogues with favorable pharmacodynamic and pharmacokinetic profiles. The present study aimed to assess the changes in lipid profile and sodium levels in patients with epilepsy taking ESL as adjunctive therapy.
Effects of eslicarbazepine acetate on lipid profile and sodium levels in patients with epilepsy / Pulitano, Patrizia; Franco, Valentina; Mecarelli, Oriano; Brienza, Marianna; Davassi, Chiara; Russo, Emilio. - In: SEIZURE. - ISSN 1059-1311. - 53:(2017). [10.1016/j.seizure.2017.09.023]
Effects of eslicarbazepine acetate on lipid profile and sodium levels in patients with epilepsy
Pulitano, Patrizia;Mecarelli, Oriano;Brienza, Marianna;Davassi, Chiara;
2017
Abstract
Several studies have demonstrated that treatment with enzyme-inducing antiepileptic drugs is associated with increased serum lipid levels. Eslicarbazepine acetate (ESL) is a novel antiepileptic drug specifically designed with the objective to identify carbamazepine and oxcarbazepine analogues with favorable pharmacodynamic and pharmacokinetic profiles. The present study aimed to assess the changes in lipid profile and sodium levels in patients with epilepsy taking ESL as adjunctive therapy.File | Dimensione | Formato | |
---|---|---|---|
Pulitano_effects-eslicarbazepine-acetate_2017.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
445.68 kB
Formato
Adobe PDF
|
445.68 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.